Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CERo Therapeutics Holdings ( (CERO) ) just unveiled an announcement.
On June 11, 2025, CERo Therapeutics Holdings received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement for its common stock. However, by July 7, 2025, the company regained compliance, ensuring its continued listing and trading on the Nasdaq Capital Market, thus averting potential delisting and maintaining its market presence.
The most recent analyst rating on (CERO) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on CERo Therapeutics Holdings stock, see the CERO Stock Forecast page.
More about CERo Therapeutics Holdings
CERo Therapeutics Holdings, Inc. operates in the biotechnology industry, focusing on developing innovative therapeutic solutions. The company is primarily engaged in the research and development of novel treatments for various diseases, with a market focus on advancing healthcare through cutting-edge biotechnological applications.
Average Trading Volume: 1,202,432
Technical Sentiment Signal: Sell
Current Market Cap: $4.6M
Find detailed analytics on CERO stock on TipRanks’ Stock Analysis page.